HaiChang Biotech Defies Market Downturn, Surges Over 10% on First Day of OTC Listing

HaiChang Biotech (7814-TW) officially commenced trading on the OTC market today (16th) at NT$28.47 per share. Bolstered by consistent overseas regulatory approvals and a significant revenue surge in June, the company defied a weak overall market, reaching a peak of NT$32.15 in early trading—up over 10%—successfully delivering a strong 'honeymoon performance.'

The stock opened at NT$32.00 and hit a high of NT$32.15. As of 10:30 AM, the share price stood at NT$30.95, up more than 8%, with approximately 500 shares traded.

Driven by demand in both the Taiwan and overseas markets, HaiChang Biotech reported June revenues of NT$14.7 million, representing a year-on-year increase of 209%. The company has achieved repeated successes abroad, recently securing three high-risk medical device marketing approvals in Thailand. It is also expected to obtain Class III medical device certifications in the Philippines and Vietnam in the near term, solidifying its presence across Southeast Asia.

Additionally, the company's innovative Bio-ink product is scheduled for export to the European market by the end of this year, further expanding its international footprint into Europe and North America.

In high-end medical device R&D, HaiChang Biotech's self-developed 'biodegradable ureteral stent' has already received a Taiwan invention patent and is expected to soon secure patents in the United States, Europe, and China. Meanwhile, its collagen regeneration patch has entered the pilot production phase.